Barcha huquqlar himoyalangan.
75.67
0.00 (0.00%)
Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
HOLX's Global Women's Health Index shows STI testing stagnates at 10%, leaving nearly 2 billion women at risk despite gains in other screenings.
Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.
WASHINGTON--(BUSINESS WIRE)---- $HOLX #gallup--1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates.
HOLX expands its GYN Surgical reach with MyoSure, NovaSure and Gynesonics boost as the global women's health devices market grows and minimally invasive demand rises.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
There is no data to display
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2026.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #EricaWheeler--Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening.
